Bio Medica Lab — 360° view

Bio Medica Lab, a company in the Pharmaceuticals industry, reported revenue of ₹22 crore and net profit of ₹3.00 crore for the September 2026 quarter.

Bio Medica Lab (NSE: BMLL-SM) closed at ₹160.70 on 20 Nov 2026. Its market capitalisation is ₹202 crore and it trades at 12.9 times earnings.

Share price
₹160.70 (20 Nov 2026)
Market cap
₹202 Cr (20 Nov 2026)
P/E
12.90 (20 Nov 2026)
Revenue
₹22 Cr (September 2026 quarter)
Net profit
₹3 Cr (September 2026 quarter)
ROCE
41.2% (FY26)
ROE
57.7% (FY26)
Book value
₹55.6 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹181.00 / ₹119.10 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: BMLL-SM

Incorporated in August 2015, Bio Medica Laboratories Ltd specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the -counter (OTC) medications

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.